This prospective single-arm clinical trial demonstrated that 177Lu-PSMA-I&T RLT achieve favourable response and significantly improved QOL in East Asian patients with mCRPC with well tolerance, which associates with significant PSA decline and tumor remission including adenopathy and bone metastasis. Here, FOLH1 is linked to lymphatic system disorder.